title: [Influence of dose and modalities of administration of BIM 23014 on growth hormone secretion in patients with acromegaly].
abstract: Somatostatin analogs, with prolonged half-lives have been proposed for the treatment of acromegalics. The aim of the study was to evaluate the short term efficacy of different doses and modalities of administration of the new somatostatin analog, BIM 23014 (BIM), on GH secretion in acromegalics. Ten acromegalics, with evolutive disease, who previously had had transsphenoidal surgery (and pituitary radiotherapy in 8) were evaluated in a three step study. The first part included four patients who received in a random order either vehicle or 500, 1000 and 1500 micrograms BIM for a day as a continuous s.c. infusion using programmable pumps at one-week interval for 24 hours to measure plasma GH levels. The second part included six patients who received in a random order either vehicle or 1500 micrograms/24h BIM as 500 micrograms x 3 s.c. injections, 750 micrograms x 2 s.c. injections and a continuous s.c. infusion using programmable pumps at one-week interval. During each period of the study blood was sampled at 4 hour intervals for 24 hours in order to measure plasma GH and BIM levels by radioimmunoassays. The third part of the study included the same 6 patients as the second part, who received 30 mg IM of a long acting formulation of BIM. Blood was sampled before and thereafter on days 1, 3, 6, 9, 12, 15, 18 and 21 following the injection for measurement of plasma GH and BIM levels. In first group 500 micrograms BIM slightly decreased plasma GH levels.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Groupe Hospitalo-universitaire de Recherche en Hormonologie, Institut Européen de Recherche Multidisciplinaire sur les Peptides, Bois Guillaume, Paris.
authors.forename: J M
authors.initials: JM
authors.lastname: Kuhn
authors.forename: C
authors.initials: C
authors.lastname: Basin
authors.forename: C
authors.initials: C
authors.lastname: Beaudoin
authors.forename: P
authors.initials: P
authors.lastname: Emy
authors.forename: M
authors.initials: M
authors.lastname: Mollard
authors.forename: B
authors.initials: B
authors.lastname: de Rougé
authors.forename: B
authors.initials: B
authors.lastname: Schatz
mesh_terms: D000172:Acromegaly / Q000378:metabolism*; D000328:Adult; D000704:Analysis of Variance; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology*; D013004:Somatostatin / Q000031:analogs & derivatives*
chemical_list: D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D013006:Growth Hormone
vernacular_title: Influence de la dose et des modalités d'administration du BIM 23014 sur la sécrétion d'hormone de croissance de l'acromégale.